Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
Celine Johanna van de LaarCarly A JanssenMatthijs JanssenMartijn A H Oude VoshaarMaiwenn J AlMart A F J van de LaarPublished in: PloS one (2022)
Allopurinol and febuxostat were both cost-effective compared to No ULT. Febuxostat was cost-effective in comparison with allopurinol at higher willingness-to-pay thresholds. For treating gout flares, colchicine, naproxen and prednisone offered comparable health economic implications, although naproxen was the favoured option.